Abacus Wealth Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$758K Sell
15,818
-2,314
-13% -$99.4K 0.08% 94
2026
Q1
$666K Sell
18,132
-8,533
-32% -$404K 0.06% 161
2025
Q4
$1.36M Buy
+26,665
New +$1.36M 0.13% 72

Other funds holding NVO

Abacus Wealth Partners's NVO Position: Q2 2026 in Review

Abacus Wealth Partners reduced its Novo Nordisk (NVO) stake by 13% in Q2 2026, selling an estimated $99.4K and leaving 15,818 shares worth $758K. The position accounts for 0.08% of the portfolio, ranked #94.

Abacus Wealth Partners first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.36M in Q4 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Abacus Wealth Partners held 15,818 shares of Novo Nordisk worth $758K as of Q2 2026.
  • Abacus Wealth Partners sold 2,314 Novo Nordisk shares in Q2 2026, an estimated $99.4K.
  • Novo Nordisk made up 0.08% of Abacus Wealth Partners's portfolio in Q2 2026, its #94 holding.
  • Abacus Wealth Partners first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Abacus Wealth Partners's Novo Nordisk position peaked at $1.36M in Q4 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.